Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

NCT07708961 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

60

Enrollment

OTHER

Sponsor class

Stopped Pending receipt of study drug from sponsor

Conditions

Glioblastoma, IDH-Wildtype

Interventions

PROCEDURE: Archive Sample Retrieval
PROCEDURE: Biospecimen Collection
PROCEDURE: Chest Radiography
PROCEDURE: Echocardiography Test
DRUG: EGFR/EGFRvIII Inhibitor WSD0922-FU
PROCEDURE: Magnetic Resonance Imaging
DRUG: Temozolomide

Sponsor

Mayo Clinic